Skip to main content

Table 1 Patient Characteristics

From: MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Patient characteristic All patients Patients with MRP3 IHC Data Patients with MRP3 mRNA Data
# of Patients 94 46 67
Gender:    
   Male 59 (63%) 30 (65%) 39 (42%)
   Female 35 (37%) 16 (35%) 28 (59%)
Age:    
   ≤ 45 years 22 (23%) 10 (22%) 13 (19%)
   >45 years 72 (77%) 36 (78%) 54 (81%)
KPS:    
   90-100 51 (54%) 23 (50%) 38 (57%)
   70 - 80 36 (38%) 21 (46%) 24 (36%)
   50 - 60 5 (5%) 2 (4%) 3 (4%)
   Unknown 2 (2%) 0 2 (3%)
Extent of Resection:    
   GTR 75 (80%) 34 (74%) 55 (82%)
   STR 17 (18%) 10 (22%) 12 (18%)
   Biopsy 2 (2%) 2 (4%) 0
Post-operative Treatment:    
   CPT-11 2 (2%) 2 (4%) 1 (1%)
   CPT-11/Celebrex 2 (2%) 2 (4%) 0
   Cyclophosphamide/Thalidomide 1 (1%) 1 (2%) 0
   Gliadel 4 (4%) 2 (4%) 2 (3%)
   Gliadel→XRT 7 (7%) 5 (11%) 7 (10%)
   Gliadel→XRT/Temo 4 (4%) 2 (4%) 2 (3%)
   Mab I131-81C6 8 (9%) 5 (11%) 7 (10%)
   Temozolomide 3 (3%) 2 (4%) 2 (3%)
   Temozolomide/CPT-11 1 (1%) 0 1 (1%)
   Temozolomide/Avastin 1 (1%) 0 1 (1%)
   Vincristine/Cisplatin/Cyclophosphamide 1 (1%) 1 (2%) 0
   XRT 19 (20%) 12 (26%) 15 (22%)
   XRT/Temo 37 (39%) 11 (24%) 26 (39%)
   None/Unknown 4 (4%) 1 (2%) 3 (4%)
Survival Status:    
   Alive 7 (7%) 3 (7%) 5 (7%)
   Dead 87 (93%) 43 (93%) 62 (93%)
Available Data:    
   RNA only 48 (51%) 0 48 (72%)
   IHC only 27 (29%) 27 (59%) 0
   RNA and IHC 19 (20%) 19 (41%) 19 (28%)
  1. Abbreviations: IHC: immunohistochemical, GTR: Gross Total Resection, STR: Subtotal Resection, XRT: External Beam Radiation Therapy.